Buspirone developmental disorders

While some anecdotal evidence has suggested possible benefit from buspirone in children (Zwier and Rao, 1994), in the study by Pfeffer (1997), only 3 of the 19 children who completed the study continued on buspirone after the study. The benefits of buspirone in children with anxiety disorders continue to be unproven. However, open-label studies have demonstrated reductions in anxiety in children with pervasive developmental disorders (Buitelaar et al., 1998). 

Buitelaar, J.K., van der Gaag, R.J., and van der Hoeven, J. (1998) Buspirone in the management of anxiety and irritability in children with pervasive developmental disorder results of an open-label study. / Clm Psychiatry 59 56—59. 

The efficacy and safety of buspirone have been evaluated in the management of anxiety and irritability in 22 children with pervasive developmental disorders. One child developed abnormal involuntary movements of the mouth, cheeks, and tongue after having taken buspirone 20 mg/day for 10 months. No other drugs were prescribed. The abnormal movements disappeared completely within 2 weeks of withdrawal of buspirone. Other adverse effects... 

---

See also in sourсe #XX -- [ ]

---